The Food and Drug Administration “could not arrive at a favorable benefit-risk assessment” for the company’s drug, relacorilant, without more evidence of its effectiveness, the Redwood City, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback